High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study

被引：22

作者：

Reyes, Henry D. ^{[1
]}

Miecznikowski, Jeffrey ^{[2
]}

Gonzalez-Bosquet, Jesus ^{[1
]}

Devor, Eric J. ^{[1
]}

Zhang, Yuping ^{[1
]}

Thiel, Kristina W. ^{[1
]}

Samuelson, Megan I. ^{[3
]}

McDonald, Megan ^{[1
]}

Stephan, Jean-Marie ^{[1
]}

Hanjani, Parviz ^{[4
]}

Guntupalli, Saketh ^{[5
]}

Tewari, Krishnansu S. ^{[6
]}

Backes, Floor ^{[7
]}

Ramirez, Nilsa ^{[8
]}

Fleming, Gini F. ^{[9
]}

Filiaci, Virginia ^{[10
]}

Birrer, Michael J. ^{[11
]}

Leslie, Kimberly K. ^{[1
]}

机构：

[1] Univ Iowa, Holden Comprehens Canc Ctr, Dept Obstet & Gynecol, Iowa City, IA 52242 USA

[2] SUNY Univ Buffalo, Dept Biostat, Buffalo, NY USA

[3] Univ Iowa, Holden Comprehens Canc Ctr, Dept Pathol, Iowa City, IA 52242 USA

[4] Abington Mem Hosp, Dept Gynecol Oncol, Hanjani Inst Gynecol Oncol, Abington, PA 19001 USA

[5] Univ Colorado Denver, Dept Obstet & Gynecol, Aurora, CO USA

[6] Univ Calif Irvine, Med Ctr, Div Gynecol Oncol, Orange, CA USA

[7] Ohio State Univ, Med Ctr, Dept Div Obstet & Gynecol, Columbus, OH 43210 USA

[8] Nationwide Childrens Hosp, Res Inst, Dept Pathol, Columbus, OH USA

[9] Univ Chicago, Sect Med Oncol, Chicago, IL 60637 USA

[10] Roswell Pk Canc Inst, NRG Oncol, Gynecol Oncol Grp, Biostat & Data Ctr, Buffalo, NY 14263 USA

[11] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA

来源：

GYNECOLOGIC ONCOLOGY | 2017年 / 146卷 / 02期

关键词：

PHASE-III TRIAL; OVEREXPRESSION; CARCINOMA; CHEMOTHERAPY; PROGNOSIS; PROLIFERATION; METASTASIS; MIGRATION; SUGGESTS; TUMORS;

D O I：

10.1016/j.ygyno.2017.05.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective. Gynecologic Oncology Group (GOG) 177 demonstrated that addition of paclitaxel to a backbone of adriamycin/cisplatin improves overall survival (OS) and progression-free survival (PFS) for patients with advanced or recurrent endometrial cancer. Using patient specimens from GOG-177, our objective was to identify potential mechanisms underlying the improved clinical response to taxanes. Stathmin (STMN1) is a recognized poor prognostic marker in endometrial cancer that functions as a microtubule depolymerizing protein, allowing

引用

页码：247 / 253

页数：7

共 50 条

[41] Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study
Fleming, Gini F.
Filiaci, Virginia L.
Marzullo, Brandon
Zaino, Richard J.
Davidson, Susan A.
Pearl, Michael
Makker, Vicky
Burke, James J., II
Zweizig, Susan L.
Van Le, Linda
Hanjani, Parviz
Downey, Gordon
Walker, Joan L.
Reyes, Henry D.
Leslie, Kimberly K.
GYNECOLOGIC ONCOLOGY, 2014, 132 (03) : 585 - 592
[42] A phase II trial of amonafide in patients with endometrial cancer - A gynecologic oncology group study
Asbury, R
Blessing, JA
Reid, GC
McGuire, WP
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (04): : 406 - 407
[43] SURGICAL PATHOLOGICAL SPREAD PATTERNS OF ENDOMETRIAL CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
CREASMAN, WT
MORROW, CP
BUNDY, BN
HOMESLEY, HD
GRAHAM, JE
HELLER, PB
CANCER, 1987, 60 (08) : 2035 - 2041
[44] Prognostic significance of pretreatment thrombocytosis in endometrial cancer: an Israeli Gynecologic Oncology Group study
Tal, Ori
Eitan, Ram
Gemer, Ofer
Helpman, Limor
Vaknin, Zvi
Leytes, Sofia
Lavie, Ofer
Ben-Arie, Alon
Amit, Amnon
Namazov, Ahmet
Ben Shahar, Inbar
Atlas, Ilan
Bruchim, Ilan
Levy, Tally
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (11) : 1437 - 1442
[45] Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study
Olawaiye, Alexander B.
Java, James J.
Krivak, Thomas C.
Friedlander, Michael
Mutch, David G.
Glaser, Gretchen
Geller, Melissa
O'Malley, David M.
Wenham, Robert M.
Lee, Roger B.
Bodurka, Diane C.
Herzog, Thomas J.
Bookman, Michael A.
GYNECOLOGIC ONCOLOGY, 2018, 151 (01) : 18 - 23
[46] Chemotherapy Completion in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer-An NRG Oncology/Gynecologic Oncology Group Study
不详
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2017, 72 (08) : 481 - 482
[47] A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
Jandial, Danielle A.
Brady, William E.
Howell, Stephen B.
Lankes, Heather A.
Schilder, Russell J.
Beumer, Jan H.
Christner, Susan M.
Strychor, Sandra
Powell, Matthew A.
Hagemann, Andrea R.
Moore, Kathleen N.
Walker, Joan L.
DiSilvestro, Paul A.
Duska, Linda R.
Fracasso, Paula M.
Dizon, Don S.
GYNECOLOGIC ONCOLOGY, 2017, 145 (02) : 236 - 242
[48] Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years
DiSilvestro, Paul A.
GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 479 - 486
[49] Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial
Brinton, Louise A.
Felix, Ashley S.
McMeekin, D. Scott
Creasman, William T.
Sherman, Mark E.
Mutch, David
Cohn, David E.
Walker, Joan L.
Moore, Richard G.
Downs, Levi S.
Soslow, Robert A.
Zaino, Richard
GYNECOLOGIC ONCOLOGY, 2013, 129 (02) : 277 - 284
[50] Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study
Ahmed, Amina
Deng, Wei
Tew, William
Bender, David
Mannel, Robert S.
Littell, Ramey D.
DeNittis, Albert S.
Edelson, Mitchell
Morgan, Mark
Carlson, Jay
Darus, Christopher J.
Fleury, Aimee C.
Modesitt, Susan
Olawaiye, Alexander
Evans, Anthony
Fleming, Gini F.
GYNECOLOGIC ONCOLOGY, 2018, 150 (02) : 300 - 305

← 1 2 3 4 5 →